Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,872 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.
Yasui Y, Kurosaki M, Tsuchiya K, Hayakawa Y, Hasebe C, Abe M, Ogawa C, Joko K, Ochi H, Tada T, Nakamura S, Furuta K, Kimura H, Tsuji K, Kojima Y, Akahane T, Tamada T, Uchida Y, Kondo M, Mitsuda A, Izumi N; Japanese Red Cross Liver Study Group. Yasui Y, et al. Among authors: nakamura s. Cancers (Basel). 2022 Jun 16;14(12):2975. doi: 10.3390/cancers14122975. Cancers (Basel). 2022. PMID: 35740647 Free PMC article.
Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients.
Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, Joko K, Sato S, Tamaki K, Yamasaki T, Shibata H, Shimoe T, Matsuda T, Toshikuni N, Fujioka S, Ohmoto K, Nakamura S, Kariyama K, Aikata H, Kobayashi Y, Tsutsui A. Koda M, et al. Among authors: nakamura s. Hepatol Res. 2012 Nov;42(11):1058-64. doi: 10.1111/j.1872-034X.2012.01025.x. Epub 2012 May 14. Hepatol Res. 2012. PMID: 22583706
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y. Tada T, et al. Among authors: nakamura s. Liver Int. 2020 Apr;40(4):968-976. doi: 10.1111/liv.14405. Epub 2020 Mar 1. Liver Int. 2020. PMID: 32064740
Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients.
Maeda M, Saeki I, Sakaida I, Aikata H, Araki Y, Ogawa C, Kariyama K, Nouso K, Kitamoto M, Kobashi H, Sato S, Shibata H, Joko K, Takaki S, Takabatake H, Tsutsui A, Takaguchi K, Tomonari T, Nakamura S, Nagahara T, Hiraoka A, Matono T, Koda M, Mandai M, Mannami T, Mitsuda A, Moriya T, Yabushita K, Tani J, Yagi T, Yamasaki T. Maeda M, et al. Among authors: nakamura s. Liver Cancer. 2020 Jan;9(1):50-62. doi: 10.1159/000502744. Epub 2019 Oct 22. Liver Cancer. 2020. PMID: 32071909 Free PMC article.
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
Hiraoka A, Kumada T, Tada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Toyoda H, Ohama H, Tsutsui A, Itokawa N, Hayama K, Arai T, Imai M, Nakamura S, Michitaka K, Hiasa Y, Kudo M; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group. Hiraoka A, et al. Among authors: nakamura s. Oncology. 2020;98(5):295-302. doi: 10.1159/000506293. Epub 2020 Feb 25. Oncology. 2020. PMID: 32097925
Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis.
Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Tada T, et al. Among authors: nakamura s. Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):261-268. doi: 10.1097/MEG.0000000000001734. Eur J Gastroenterol Hepatol. 2021. PMID: 32282541
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: nakamura s. J Gastroenterol Hepatol. 2021 Jul;36(7):1812-1819. doi: 10.1111/jgh.15336. Epub 2020 Nov 29. J Gastroenterol Hepatol. 2021. PMID: 33171524 Free PMC article.
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis.
Chuma M, Uojima H, Hiraoka A, Kobayashi S, Toyoda H, Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouso K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S. Chuma M, et al. Among authors: nakamura s. Hepatol Res. 2021 Feb;51(2):201-215. doi: 10.1111/hepr.13592. Epub 2021 Jan 5. Hepatol Res. 2021. PMID: 33270323
Clinical characteristics of immunoglobulin IgG4-related sclerosing cholangitis: Comparison of cases with and without autoimmune pancreatitis in a large cohort.
Naitoh I, Kamisawa T, Tanaka A, Nakazawa T, Kubota K, Takikawa H, Unno M, Masamune A, Kawa S, Nakamura S, Okazaki K; collaborators. Naitoh I, et al. Among authors: nakamura s. Dig Liver Dis. 2021 Oct;53(10):1308-1314. doi: 10.1016/j.dld.2021.02.009. Epub 2021 Mar 2. Dig Liver Dis. 2021. PMID: 33664004
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Chikara O, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), and GLSG (Gunma Liver Study Group). Hiraoka A, et al. Among authors: nakamura s. Hepatol Res. 2021 Aug;51(8):880-889. doi: 10.1111/hepr.13644. Epub 2021 May 5. Hepatol Res. 2021. PMID: 33837620
10,872 results
You have reached the last available page of results. Please see the User Guide for more information.